Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
Provided By GlobeNewswire
Last update: Aug 14, 2025
Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM)
Read more at globenewswire.com
